Traws Pharma (TRAW) Equity Average (2016 - 2025)
Historic Equity Average for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $6.4 million.
- Traws Pharma's Equity Average rose 11190.76% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 11190.76%. This contributed to the annual value of -$10.5 million for FY2024, which is 15376.47% down from last year.
- As of Q3 2025, Traws Pharma's Equity Average stood at $6.4 million, which was up 11190.76% from $7.1 million recorded in Q2 2025.
- Traws Pharma's 5-year Equity Average high stood at $47.9 million for Q4 2021, and its period low was -$53.8 million during Q3 2024.
- Moreover, its 5-year median value for Equity Average was $20.9 million (2023), whereas its average is $13.8 million.
- As far as peak fluctuations go, Traws Pharma's Equity Average surged by 42085.92% in 2021, and later tumbled by 42187.04% in 2024.
- Traws Pharma's Equity Average (Quarter) stood at $47.9 million in 2021, then crashed by 35.61% to $30.8 million in 2022, then crashed by 59.16% to $12.6 million in 2023, then tumbled by 233.64% to -$16.8 million in 2024, then surged by 138.04% to $6.4 million in 2025.
- Its Equity Average was $6.4 million in Q3 2025, compared to $7.1 million in Q2 2025 and -$12.8 million in Q1 2025.